Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald has maintained a Hold rating on Quest Diagnostics (NYSE:DGX) and increased the price target from $145 to $150.
December 20, 2023 | 4:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained a Hold rating on Quest Diagnostics and raised the price target from $145 to $150, indicating a positive outlook on the stock's value.
The increase in price target by Truist Securities suggests a positive sentiment towards Quest Diagnostics' stock value in the short term. While the Hold rating does not suggest a strong buying or selling action, the raised target implies that the stock may have room to grow, which could positively influence investor perception and potentially lead to a modest increase in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100